Literature DB >> 27586016

The genotypic study of Mycobacterium tuberculosis complex resistant to isoniazid: Galicia, Spain (2008-2013).

M L Pérez Del Molino1, G Barbeito-Castiñeiras2, B Mejuto3, P Alonso4, A Fernández5, G González-Mediero6.   

Abstract

Incorporation of rapid detection systems to identify mutations in M. tuberculosis complex that confer resistance to isoniazid and rifampicin has potentiated the knowledge of their distribution, given the geographical variability. We performed antibiograms of the 2,993 strains isolated in Galicia, Spain (2008-2013). In the strains resistant to isoniazid, a concentration of 0.4 mg/mL and MTBDRplus Genotype test (Hain Lifescience, Germany) were used. We found that 3.64 % of strains were resistant to isoniazid, while 0.43 % were resistant to isoniazid and rifampicin (multidrug resistant, MDR). The MTBDRplus test showed an overall sensitivity of 72.48 %, with 62.5 % sensitivity for non MDR isoniazid-resistant strains and 100 % sensitivity for MDR strains. The katG gene mutation was detected at codon 315 in 38.53 % of strains. The S315T mutation appeared in 61.54 % of MDR strains and 34.38 % of non-MDR strains. The 28.44 % had mutations in inhA, (93.55 % in C15T), and 38.46 % of MDR strains were mutated. In non-MDR strains, 37.50 % were wild-type, 35.42 % and 27.08 % had mutations in katG and inhA, respectively. The most frequent mutation in rpoβ was S531L (46.15 %). The 38.71 % and 41.9 % of strains with resistance to isoniazid and streptomycin had mutations in katG and inhA, respectively (2 strains with mutations in T8C and T8A). The distribution pattern of resistance among strains with high and low concentrations of isoniazid showed statistically significant differences in relation to the mutation in katG and wild-type. The sensitivity of the Genotype MTBDRplus test for non-MDR strains in our area was at the lower threshold described.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27586016     DOI: 10.1007/s10096-016-2730-9

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  20 in total

1.  High prevalence of KatG Ser315Thr substitution among isoniazid-resistant Mycobacterium tuberculosis clinical isolates from northwestern Russia, 1996 to 2001.

Authors:  Igor Mokrousov; Olga Narvskaya; Tatiana Otten; Elena Limeschenko; Lidia Steklova; Boris Vyshnevskiy
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

2.  Molecular investigation of resistance to the antituberculous drug ethionamide in multidrug-resistant clinical isolates of Mycobacterium tuberculosis.

Authors:  F Brossier; N Veziris; C Truffot-Pernot; V Jarlier; W Sougakoff
Journal:  Antimicrob Agents Chemother       Date:  2010-10-25       Impact factor: 5.191

3.  Population genetics study of isoniazid resistance mutations and evolution of multidrug-resistant Mycobacterium tuberculosis.

Authors:  Manzour Hernando Hazbón; Michael Brimacombe; Miriam Bobadilla del Valle; Magali Cavatore; Marta Inírida Guerrero; Mandira Varma-Basil; Helen Billman-Jacobe; Caroline Lavender; Janet Fyfe; Lourdes García-García; Clara Inés León; Mridula Bose; Fernando Chaves; Megan Murray; Kathleen D Eisenach; José Sifuentes-Osornio; M Donald Cave; Alfredo Ponce de León; David Alland
Journal:  Antimicrob Agents Chemother       Date:  2006-08       Impact factor: 5.191

4.  Revisiting susceptibility testing in MDR-TB by a standardized quantitative phenotypic assessment in a European multicentre study.

Authors:  E Cambau; M Viveiros; D Machado; L Raskine; C Ritter; E Tortoli; V Matthys; S Hoffner; E Richter; M L Perez Del Molino; D M Cirillo; D van Soolingen; E C Böttger
Journal:  J Antimicrob Chemother       Date:  2014-11-11       Impact factor: 5.790

5.  The GenoType® MTBDRplus assay for detection of drug resistance in Mycobacterium tuberculosis in Sweden.

Authors:  Erja Chryssanthou; Kristian Angeby
Journal:  APMIS       Date:  2011-11-28       Impact factor: 3.205

6.  Epidemiology of isoniazid resistance mutations and their effect on tuberculosis treatment outcomes.

Authors:  Mai N T Huyen; Frank G J Cobelens; Tran N Buu; Nguyen T N Lan; Nguyen H Dung; Kristin Kremer; Edine W Tiemersma; Dick van Soolingen
Journal:  Antimicrob Agents Chemother       Date:  2013-05-20       Impact factor: 5.191

7.  Rapid genotypic assays to identify drug-resistant Mycobacterium tuberculosis in South Africa.

Authors:  Joanna Evans; Michael C Stead; Mark P Nicol; Heidi Segal
Journal:  J Antimicrob Chemother       Date:  2008-10-21       Impact factor: 5.790

8.  Characterization of the catalase-peroxidase gene (katG) and inhA locus in isoniazid-resistant and -susceptible strains of Mycobacterium tuberculosis by automated DNA sequencing: restricted array of mutations associated with drug resistance.

Authors:  J M Musser; V Kapur; D L Williams; B N Kreiswirth; D van Soolingen; J D van Embden
Journal:  J Infect Dis       Date:  1996-01       Impact factor: 5.226

9.  Evaluation of the GenoType MTBDRplus assay for rifampin and isoniazid susceptibility testing of Mycobacterium tuberculosis strains and clinical specimens.

Authors:  Doris Hillemann; Sabine Rüsch-Gerdes; Elvira Richter
Journal:  J Clin Microbiol       Date:  2007-05-30       Impact factor: 5.948

10.  Novel katG mutations causing isoniazid resistance in clinical M. tuberculosis isolates.

Authors:  Jessica N Torres; Lynthia V Paul; Timothy C Rodwell; Thomas C Victor; Anu M Amallraja; Afif Elghraoui; Amy P Goodmanson; Sarah M Ramirez-Busby; Ashu Chawla; Victoria Zadorozhny; Elizabeth M Streicher; Frederick A Sirgel; Donald Catanzaro; Camilla Rodrigues; Maria Tarcela Gler; Valeru Crudu; Antonino Catanzaro; Faramarz Valafar
Journal:  Emerg Microbes Infect       Date:  2015-07-15       Impact factor: 7.163

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.